BNT162b2 vaccines – Communicable Diseases Research

Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines

COVID-19 백신 접종 후 면역 장수: 현재 승인된 백신에 대한 종합 검토

Review

Published on 2022-11-302022-09-12
Journal: Human vaccines & immunotherapeutics
[Category] MERS, 진단,

Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity

중증 비만 환자의 SARS-CoV-2 백신에 대한 항체 반응

Article

Published on 2022-09-012022-09-11
Journal: Obesity surgery
[Category] COVID19(2023년), MERS, SARS, 진단, 치료법,

[키워드] age antibody antibody level antibody levels Antibody Response Antibody titer Antibody titers anticipated Antigen blood sample Blood samples BMI BNT162b2 BNT162b2 mRNA BNT162b2 vaccine BNT162b2 vaccines consecutive patient Control control group CoronaVac Course COVID-19 COVID-19 vaccination determined by disease domain dose dose of vaccination Effectiveness enrolled female IgG antibody IgG antibody titers inactivated individual Infection information male mRNA normal weight not significantly different obesity of BNT162b2 Patient presenting Quantitative recruited reduced response SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG antibody SARS-COV-2 infection SARS-CoV-2 spike antigen SARS-CoV-2 vaccination SARS-CoV-2 vaccine serological Severe obesity significantly significantly higher significantly lower spike-protein subject vaccination Vaccine Vaccines Vaccines. vulnerable population was performed weight control were measured
[DOI] 10.1007/s11695-022-06181-y PMC 바로가기 [Article Type] Article

A case series of severe breakthrough infections observed in nine patients with COVID-19 in a southwestern German university hospital

독일 남서부 대학 병원에서 9명의 COVID-19 환자에서 관찰된 일련의 심각한 돌발 감염 사례

Article

Published on 2022-06-012022-09-11
Journal: Infection
[Category] COVID19(2023년), SARS, 변종,

[키워드] addition advanced age age analyzed avoidance B.1.617.2 behavioural BNT162b2 BNT162b2 vaccines booster vaccination Breakthrough infection cardiorespiratory case sery Comorbidities Complete Course COVID-19 death delta variant disease dose effective Face masks FIVE high risk high-risk area high-risk areas Hospitalization Hospitalized hospitalized patient immunization Increased Infection Intensive intensive care lack measure Measures median median age nine of BNT162b2 Patient patients patients died patients with COVID-19 Pfizer-BioNTech preventive measures Protective question raise risk factor Risk factors SARS-CoV-2 suffered symptom onset Travel two patients U/mL university hospital vaccination Vaccine vaccine breakthrough.
[DOI] 10.1007/s15010-022-01797-9 PMC 바로가기 [Article Type] Article

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

면역 저하 환자의 COVID-19 mRNA 백신에 의한 우려 변종에 대한 체액 반응

Article

Published on 2022-05-012022-09-11
Journal: JAMA Oncology
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] 2019-nCoV Against age All participant All participants Alpha anti-spike antibody Antibody titer Antibody titers association Autoimmune disease Autoimmune diseases best Beta Beta variant binding BNT162b2 BNT162b2 vaccine BNT162b2 vaccines Cancer cancers circulating concern conducted COVID-19 decrease Delta delta variant Delta variants dose Effectiveness elicited enrolled female Gamma greater healthy control healthy controls hematologic Humoral response humoral responses IgG Immunocompromised patient Immunocompromised patients median Messenger RNA Moderna mRNA mRNA vaccine mRNA-1273 NAb NAb responses NAbs nCoV neutralizing antibody neutralizing antibody titers outcome participant Participants Patient patient population performed persistence Pfizer-BioNTech Primary outcome proportion proportions response response to vaccination responses against SARS-CoV-2 SARS-CoV-2 variants secondary outcome solid cancers solid organ solid organ transplant solid organ transplants study group the healthy the patient the SARS-CoV-2 Treatment underlying disease university vaccination vaccination schedule Vaccine Vaccines variant variants variants of concern VoC VOCs were measured
[DOI] 10.1001/jamaoncol.2022.0446 PMC 바로가기 [Article Type] Article

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron

백신은 SARS-CoV-2 Omicron에 대해 고도로 보존된 세포 면역을 유도합니다

Article

Published on 2022-03-012022-09-11
Journal: Nature
[Category] MERS, SARS, 변종, 진단,

[키워드] Ad26 Ad26.COV2.S B.1.1.529 BNT162b2 BNT162b2 vaccine BNT162b2 vaccines CD4 CD8 cellular cellular immune responses cellular immunity conserved contribute cross-reactivity Delta demonstrated effector memory elicit elicited evade fraction immune responses immunological individual Infection mutated Neutralizing antibody response neutralizing antibody responses observation omicron Omicron variants reduced robust SARS-CoV-2 SARS-COV-2 infection severe disease severe SARS severe SARS-CoV-2 shown Spike protein subpopulations T cell T cell response T cell responses the SARS-CoV-2 These data Vaccine variant variants WA1/2020
[DOI] 10.1038/s41586-022-04465-y PMC 바로가기 [Article Type] Article

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England

Research Article

Published on 2022-02-222022-10-29
Journal: PLoS Medicine
[Category] COVID-19, COVID19(2023년), SARS,

[키워드] absolute increase Accuracy adjusted Adults age age and sex analysed analysis anticoagulant medication antiplatelet Asian association black blood pressure BNT162b2 BNT162b2 vaccines case finding ChAdOx1 ChAdOx1-S coded cohort study confidence interval confounding factors Coronavirus infection covariate covariates COVID-19 COVID-19 mortality COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Deprivation diabetes diagnostic dose DVT Effect effort Electronic health record Electronic health records England estimate estimates event first vaccination Frequency hazard ratio healthcare Hospital admission hospitalisation hospitalised HRs hypertension identify IMPROVE incidence incidence rate increase in increased risk increases in limitation medication morbidity morbidity and mortality Myocardial infarction outcome performed Platelet population level population-based cohort Positive predictive value prevaccination Rate reducing reported researcher residual confounding risk selected Sex smoking stroke therapy threshold thrombosis thrombotic event Thrombotic events vaccination Vaccine Vaccines venous Venous thrombosis white William
[DOI] 10.1371/journal.pmed.1003926 PMC 바로가기 [Article Type] Research Article

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Covid-19 백신에 의한 경증 및 중증 질병에 대한 보호 기간

Article

Published on 2022-01-272022-09-11
Journal: The New England Journal of Medicine
[Category] 변종,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adults age Alpha B.1.1.7 B.1.617.2 BNT162b2 BNT162b2 vaccine BNT162b2 vaccines Case-control cause ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1-S clinical risk clinically condition coronavirus coronavirus disease Coronavirus disease 2019 death delta variant dose Duration effective Effectiveness England greater healthy Hospitalization less medical condition Older peaked protection real-world data receipt SARS-CoV-2 second dose severe acute respiratory syndrome Coronavirus severe disease shown status symptomatic COVID-19 the vaccine United Kingdom vaccination Vaccine vaccine dose variant variants virus
[DOI] 10.1056/NEJMoa2115481 PMC 바로가기 [Article Type] Article

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

델타의 중화 감소 (B.1.617.2) 예방 접종 후 SARS-COV-2 우려 변형

Research Article

Published on 2021-12-022022-08-13
Journal: PLoS Pathogens
[Category] Biochemistry, SARS, 변종, 진단,

[키워드] (Beta accumulation African antibody Antibody titre antigenic antigenic drift antigenic profiles assessment Astra Zeneca Author B.1.351 B.1.617.1 B.1.617.2 bat bats Beta BNT162b2 BNT162b2 vaccines Booster vaccine booster vaccines ChAdOx1 changes in collected COVID-19 COVID19 death decrease decreases Delta delta variant dose effective Effectiveness Efficacy elicited evade expressed facilitate fold Fold changes glycoprotein groups hospitalisation Human human cell human cells humans Immunity India indicated individual Infection Lineage magnitude Mutation neutralisation neutralise Neutralising Antibodies neutralising antibody titres of BNT162b2 Pfizer Pfizer/BioNTech Prevent profile protective immune response pseudoviruses recipient recipients reduced reduction reduction in reductions reductions in required risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus sensitivity sera Severe infection shape significantly higher South South Africa spike glycoprotein spike glycoproteins Spike protein subsequent the spike protein titre vaccinated individuals vaccination Vaccine vaccine efficacy Vaccines variant variant B.1.617.2 variants variants of concern Viral viral variant Viral variants virus Virus spike VOCs while with infection with infections Wuhan Wuhan, China
[DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article

Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection

SARS-COV-2 mRNA 백신에 대한 체액 반응 : 과거 감염의 역할

Research Article

Published on 2021-11-082022-09-10
Journal: PLoS ONE
[Category] MERS, SARS, 진단, 치료기술,

[키워드] antibody Antibody titers biologic BNT162b2 BNT162b2 vaccine BNT162b2 vaccines booster completion decay demonstrated Department detect dose enrolled fire first responders Health Service Humoral response humoral responses immune responses immunoassay implication individual individuals infected individual Infection Los Angele Los Angeles magnitude median Microparticle mRNA mRNA vaccine mRNA-1273 mRNA-based vaccine mRNA-based vaccines naïve naïve individuals NPI pandemic protective immune response remains uncertain required respiratory Responder robust antibody response robust antibody responses role SARS-CoV-2 SARS-CoV-2 spike Severe acute respiratory syndrome spike subset two-dose regimen understanding University of California Vaccine vaccine dose vaccinee vaccinees was used
[DOI] 10.1371/journal.pone.0259703 PMC 바로가기 [Article Type] Research Article

Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study

nCoV-19 백신 접종 후 과응고의 부재: 관찰 파일럿 연구

Observational Study

Published on 2021-09-012022-09-11
Journal: Thrombosis research
[Category] SARS, 임상, 치료기술,

[키워드] activating Activation ADP age aggregation BNT162b2 BNT162b2 vaccine BNT162b2 vaccines Care carriers ChAdOx1 ChAdOx1 vaccine ChAdOx1 vaccines clinically Coagulation Cohort comparable control group controls COVID-19 COVID-19 vaccine COVID-19 vaccines eligible endogenous evaluated fibrinogen first dose Gender groups Health Health care healthy subject healthy subjects hypercoagulability hypercoagulable induce no difference no differences oral contraceptive oral contraceptives parameter peptide pilot study plasma Platelet platelet aggregation Platelet count predisposition professional prothrombotic state receptor SARS-CoV-2 subject thrombin Thrombin generation thrombin receptor Thrombophilia thrombosis TRAP university vaccination vaccine. Volunteer Whole blood women
[DOI] 10.1016/j.thromres.2021.06.016 PMC 바로가기 [Article Type] Observational Study